In a healthcare update, Prescribers are advised not to start new patients on Ozempic until all information about the product and its potential benefit to risk ratio and supply situation is evaluated. The pharmaceutical giant that markets Ozempic, Novo Nordisk, has recently advised the TGA and the Ozempic Medicine Shortage Action Group that supply will be limited for the rest of 2023 and throughout 2024.